TRPV2 (transient receptor potential vanilloid type 2) antagonist (IC50 = 0.46 μM). Selective for TRPV2 over TRPV1, TRPV3 and TRPV4 expressed in HEK293 cells. Inhibits lyosphosphatidic acid (LPA)-induced prostate cancer cell migration in vitro.

2313525-20-9

C17H21F3N4O2S

402.44

SET 2

DMSO:40.24 mg/mL(100 mM)
Ethanol:20.12 mg/mL(50 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years